NextCure, Inc. (NXTC) Stock Score, Valuation & Financial Research

NextCure, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for NXTC

NextCure, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 6.42. These figures are a research snapshot, not a buy or sell recommendation.

What NextCure, Inc. does

NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

NextCure is a clinical-stage biopharmaceutical company that generates revenue primarily through research and development collaborations and licensing agreements. The company focuses on discovering and developing novel immunomedicines for cancer and other diseases, seeking to monetize its proprietary technology through upfront payments, milestone payments, and potential future royalties from partners.

Products and services

  • The company's pipeline includes LNCB74, a B7-H4 antibody-drug conjugate (ADC), and SIM0505, a clinical-stage therapeutic candidate for cancer treatment.

Customer types

Biopharmaceutical partners.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of clinical trial materials; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Zaiming — A licensing agreement under which Zaiming retains exclusive rights to develop and commercialize certain products in China, Hong Kong, Macau, and Taiwan, while NextCure holds global rights excluding that territory. Source

Business strengths to evaluate

  • Proprietary antibody-drug conjugate (ADC) technology platform Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers for clinical supply Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

NXTC financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 6.42
Market capitalization:
23.19M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -42.75M
Free cash flow:
USD -49.61M
Cash:
USD 15.26M
Total debt:
USD 4.29M
EPS:
USD -10.58

What stands out

  • Free cash flow is USD -49.61M, negative for the stored period.
  • The balance sheet shows USD 15.26M of cash versus USD 4.29M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 10.97M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for NXTC

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can NXTC fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is NXTC likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for NXTC to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of NXTC's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-08.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research NXTC

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.